Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice.
The purpose of this study was to evaluate the effects of anginex on tumour angiogenesis assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) on a clinical 1.5 Tesla MR system and with the clinically available contrast agent gadopentetate dimeglumine. C57BL/6 mice carrying B16F10 melanomas were treated with anginex, TNP-470 or saline. Tumour growth curves and microvessel density (MVD) were recorded to establish the effects of treatment. DCE-MRI was performed on day 16 after tumour inoculation, and the endothelial transfer coefficients of the microvessel permeability surface-area product (K(PS)) were calculated using a two-compartment model. Both anginex and TNP-470 resulted in smaller tumour volumes (P<0.0001) and lower MVD (P <0.05) compared to saline. Treatment with anginex resulted in a 64% reduction (P<0.01) of tumour K(PS) and TNP-470 resulted in a 44% reduction (P=0.17), compared to saline. DCE-MRI with a clinically available, small-molecular contrast agent can therefore be used to evaluate the angiostatic effects of anginex and TNP-470 on tumour angiogenesis.
de Lussanet
Q G
QG
Department of Radiology, Maastricht University Hospital, and Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands.
Beets-Tan
R G H
RG
Backes
W H
WH
van der Schaft
D W J
DW
van Engelshoven
J M A
JM
Mayo
K H
KH
Griffioen
A W
AW
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D003287:Contrast Media; D019786:Gadolinium DTPA; D008279:Magnetic Resonance Imaging / Q000379:methods; D008545:Melanoma / Q000098:blood supply* / Q000188:drug therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000517:prevention & control*; D010455:Peptides; D011506:Proteins
D020533:Angiogenesis Inhibitors; D003287:Contrast Media; D010455:Peptides; D011506:Proteins; C111993:betapep-25 protein, synthetic; D019786:Gadolinium DTPA